anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided is a skin temperature elevating agent, wherein it is possible to elevate the skin temperature in a more effective manner. Also provided are a cosmetic composition, food, and sundry items which exert a skin temperature elevating effect. Specifically provided is a skin temperature elevating agent comprising the extract of Mentha arvensis var piperascens, the extract of Salvia sclarea, dihydro-beta-ionol, and/or geraniol. As a consequence, the skin temperature elevating agent elevates the temperature on the skin of the cheeks. Moreover, the skin temperature elevating agent comprises the extract of Mentha arvensis var. piperascens, the extract of Juniper berry, and/or 4-methoxystyrene. As a consequence, the skin temperature elevating agent elevates the temperature on the skin of the finger tips. Therefore, the skin temperature elevating agent can elevate skin temperature in a more effective manner. Additionally, the cosmetic composition, food, and sundry items containing said skin temperature elevating agent exert a skin temperature elevating effect.
BACKGROUND: Thermage is a monopolar radiofrequency (RF). It has become an indispensable part of facial and body youthful methods. Although the current device is constantly improving in epidermal cooling techniques and even automatically measures the local impedance value, applying surface anesthesia can take some of the pain away caused by thermage, and the patient's severe pain in the jaw and neck areas is still difficult to resolve.
METHODS: The author describes how he uses the combination of the buccal nerve block (BNB) and the superficial cervical plexus block (SCPB) to improve the comfort of the patient's face and neck treatment of patients. It can improve the quality, elasticity, and texture of the skin.
RESULTS: According to the author's knowledge of oral and maxillofacial surgery, the combination of BNB and SCPB is applied to the neck and facial analgesia. Combining the BNB and SCPB effectively provides facial and neck anesthesia. The BNB in this technique provides pain relief to the facial skin in the mandibular area and SCPB offers pain relief to the skin of the neck. RF facial rejuvenation treatment often involves the junction of the face and neck to improve the contour of the mandibular margin. Therefore, Whether the RF treatment is aimed at the face or neck, or the treatment is performed simultaneously, we advocate the block both of the buccal nerve and the superficial cervical plexus nerves to achieve perfect analgesia. Still, the dosage of anesthetic medication for the nerve block can be adjusted according to the treatment area.
CONCLUSION: We applied these two nerve blocks and their combination to improve skin laxity with RF therapy for the first time.
Women in the CBT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
Adult Onset Still Disease (AOSD) is an acquired inflammatory disease of unknown etiology, presenting with non specific symptoms. Other conditions such as cancer, infection or other inflammatory disease might mimick its symptoms. Its diagnosis rely on sets of criteria, i.e. Fautrel Criteria and Yamaguchi Criteria. However, differential diagnosis might appear during follow-up after an initial diagnosis of AOSD. The aim of this study is to assess diagnostic performance of Fautral and Yamaguchi Criteria after 18 months of follow-up, and to describe differential diagnosis appearing during follow-up.
PURPOSE:To obtain a preparation for oral administration, by adding a middle- chain fatty acid monoglycerin ester to ubidecarenone. CONSTITUTION:1pt.wt. ubidecarenone is blended with 0.5-150pts.wt. middle-chain fatty acid monoglycerin ester (e.g. capric acid, caproic acid, caprylic acid, etc.) to give a preparation for oral administration having high absorption of ubidecarenone. The middle-chain fatty acid monoglycerin ester may be mixed with a third component such as vegetable oil, etc., and used as a mixture. The blending ratio of the third component is preferably 0.2-1pt.wt. based on 1pt.wt. of the ester.
Mutant photosynthetic organisms having reduced chlorophyll and increased photosynthetic efficiency are provided. The mutant strains have mutated or attenuated: chloroplastic SRP54 gene and SGI1 gene; chloroplastic SRP54 gene and SGI2 gene; chloroplastic SRP54 gene, SGI1, and SGI2 genes are disclosed. The mutant photosynthetic organisms exhibit increased productivity with respect to wild-type strains. Also provided are mutant photosynthetic organisms having mutated or attenuated cytosolic SRP54 genes. Provided herein are methods of producing biomass and other products such as lipids using strains having mutations in an SRP54 gene, SGI1, SGI2 genes, a combination of SGI1/SRP54, and a combination of SGI2 and SRP54 genes. Also included are constructs and methods for attenuating or disrupting SRP54, SGI1, and SGI2 genes.
The students in the experimental group 2 practiced the head bath skill on the standardized patient. A standardized patient is a healthy individual pretending to be a patient.
Compositions and methods for improving brain function or enhancing learning ability or memory are provided. The compositions may include one or more agents that increase METTL3 (N 6 -adenosine-methyltransferase 70 kDa subunit) potency in at least one body part of the subject. The methods may include administering, to a subject, a composition including one or more agents that increase METTL3 potency in at least one body part of the subject. Methods for assessing learning ability or memory ability of a subject are also provided. The methods may include assessing the level of an N 6 -methyladenosine (m 6 A) -related protein in at least one body part of the subject and comparing the level of m 6 A or the m 6 A-related protein to a standard level. The methods may further include determining the learning ability or memory ability of the subject based on the comparison of the level of m6A or the m6A-related protein to the standard level.
Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 35 cycles in the absence of disease progression or unacceptable toxicity.
Innovative non-surgical methods and compositions are provided for administering PDT to promote tissue regeneration or augmentation while minimizing scarring and risk of infection. Among several areas of application, is the treatment of acute and chronic wounds which have afflicted epidermal and connective tissue layers of the body. Another application area is as cosmetic surgery/treatments, including: reducing wrinkles, sulcus, scars (acne or traumatic caused), sequelae cellulite, as well as for other skin irregularities, to give a smoother skin surface. This invention consists of a collagen based or other suitable biodegradable supporting matrix which is embedded with a liposomal loaded photosensitizer. In on embodiment of this invention a liposomal formulated photosensitize is first injected at the site followed by collagen implantation and PDT treatment. In another embodiment a liposomal formulated photosensitizer is incorporated in the collagen. Generally 30 minutes after collagen is mixed with photosensitizer the light activation is done. The matrix may also carry important growth factors and cytokines, which promote fibroblast cell migration and proliferation, to the wound site. Microbial infection at the wound site can also be controlled by antibacterial PDT.
Initially Yoga will be delivered in 1-on-1 format between the yoga therapist and the AD/caregiver dyad. Five outpatient adults, with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver, will receive at-home teleyoga classes via video conferencing. Later, yoga will be delivered in a group format. Ten outpatient adults with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver will receive group at-home teleyoga classes via video conferencing.
The present invention discloses a coded gene sequence of clam worm kinase with thrombolytic activity and an amino acid sequence thereof. The sequences are respectively shown as SEQID No. 1 and SEQID No. 2 in a sequence table, which belong to the field of medical biological engineering. The present invention has the advantages that coated genes of clam worm kinase can be cloned from various cDNA libraries of clam worms according to the DNA(mRNA) sequence of coded genes of clam worm kinase in cDNA libraries of clam worms . The coded genes can obtain recombinant expression in a eukaryon expressing system (such as a yeast cell or an animal cell) or a procaryon expressing system (such as escherichia coli) through the technology of gene recombination. The recombined clam worm kinase has thrombolysis biological activity and is new medicament in genetic engineering.
PROBLEM TO BE SOLVED: To obtain the subject medicine which accelerates the functional amelioration of transplanted hepatic tissues and its regeneration and can recover the hepatic function in the early stage after operation of liver transplantation by using a hepatocyte proliferation factor, particularly by combining the hepatocyte proliferation factor with an immunosuppressant in combination. SOLUTION: This medicine contains a hepatocyte proliferation factor or both of the hepatocyte proliferation factor and an immunosuppressant. As the hepatocyte proliferation factor, TCF-11 is preferable, particularly when the TCF-11 and the immunosuppressant are used in combination, the activity is remarkably enhanced. The TCF-11 is a well-known protein desired from human fibroblast and is obtained by the method of purifying it after concentrating the culture medium of human fibroblast and allowing it to absorb into an ion exchanger or by means of genetic engineering. The TCF-11 can be parenterally administrated as an injection and the preparation containing 0.6-600mg/day/adult, preferably 6-60mg/day/adult, as the purified TCF-11 is administrated to patients before liver-transplanting.  When the TCF-11 is used in combination with the immunosuppressant (e.g. tacrolimus), 0.1-100mg/day/adult is administrated.
Betamethasone dipropionate ointment contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

Betamethasone dipropionate is a white to cream white powder. It is practically insoluble in water, sparingly soluble in ethanol (96%) and freely soluble in acetone, in methylene chloride and in chloroform. 

Chemically, it is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21- dipropionate. The structural formula is:

Each gram of the 0.05% ointment contains 0.64 mg betamethasone dipropionate, USP (equivalent to 0.5 mg betamethasone) in an ointment base of mineral oil and white petrolatum.
The invention discloses a treatment patch for acupoint application and belongs to the field of medicines. The treatment patch comprises a bottom liner layer and a cover liner layer. A base material is arranged between the bottom liner layer and the cover liner layer and is prepared from, by weight, far-infrared ceramic powder, acrylic pressure sensitive adhesives, stainless steel beads and drug extracts. Infrared rays with the wavelength being 8-15 microns generated by the far-infrared ceramic powder act on a human body and can penetrate the superficial portion of a human body, and the main biological function is the heat effect. The heat effect can reduce excitability of pain nerves and can also improve blood circulation, accelerate absorbing of morbid substances and inflammatory exudation substances, relieve irritation and pressing on nerve endings, and therefore pain can be relieved. The stainless steel beads stimulate acupoints so that local blood vessels can be expanded, blood flow is increased, blood circulation and microcirculation are improved, and therefore local tissue metabolism and nutrition can be improved, and the treatment patch has the anti-inflammatory detumescence, spasm relieving, pain easing and immunity regulation functions.
676,738. X-ray contrast emulsions. FARBENFABRIKEN BAYER. Nov. 14, 1950 [Nov. 16, 1949], No. 27850/50. Class 81 (i). A parenterally administrable X-ray contrast agent substantially non-irritating and compatible with animal tissues and body fluids comprises a stable aqueous emulsion of an X-ray opaque ester of an iodised fatty acid containing a synthetic non-ionic emulsifier and a non-toxic water-soluble thiosulphate. The ester may be 25 to 75 per cent by weight of the emulsion, the emulsifier 1 to 5 per cent, the thiosulphate 0.5 to 5 per cent and other additions such as lecithin, grape sugar and gelatin 0.5 to 2 per cent. Specified esters are the isoamyl and isobutyl esters of diiodo behenolic acid (see U.S.A. Specifications 1,688,100 and 1,688,169). The thiosulphate is preferably sodium thiosulphate. Suitable emulsifiers are fatty acid monoesters of polyhydroxy alcohols and/or their reaction products with alkylene oxides e.g. sorbitol mono esters of lauric acid, palmitic acid, stearic acid and oleic acid; mono fatty acid esters of glycerol e.g. glycerol mono stearate and glycerol mono oleate; mono esters of glycols such as ethylene glycol, tetraethylene glycol and dodecaethylene glycol with fatty acids such as palmitic, stearic, lauric or mixtures of such fatty acids.
Women with term pregnancies whose labor started spontaneously. Spontaneous labor is determined by either spontaneous rupture of membranes at term and/or powerful, regular uterine contractions that cause cervical change. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Labor augmentation will be performed for women with inadequate uterine contractions, i.e. contractions measuring less than Montevideo units, irregular weak uterine contractions. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
PURPOSE:To obtain fine powder particles of titanium hydroxide which is hydrophobic, transparent, stable and free from flocculation and has large UV scattering effect by adding a specified silicon into the hydrolysis process of titanium alkoxide. CONSTITUTION:Water and one or more kinds of silicon expressed by formula I (wherein (n) is 3 to 7) and formula II ((n) is 1 to 4 and R is methyl or phenyl group) such as octamethyl cyclotetra siloxane are added to a solution of titanium alkoxide (i.e. tetramethoxy titanium) diluted with alcohol, etc., hydrolysis, the solution is condensed and dried to obtain fine particles of titanium hydroxide. The obtd. titanium hydroxide is suitable not only for cosmetics but also for such a usage which requires protection from UV ray. The addition of silicon may be performed after the hydrolysis of titanium alkoxide and before condensation.
INTRODUCTION: Prechtl's method (GMA) is a test for the functional assessment of the young nervous system. It involves a global and a detailed assessment of the general movements (GMs) and has demonstrated validity. Data on the reliability of both assessments in the preterm period are scarce. This study aimed to evaluate the inter-rater reliability for the global and detailed assessments of the preterm writhing GMA.
MATERIALS AND METHODS: The study participants were 69 infants born at <37 gestational weeks and admitted to the neonatal intensive care unit. They were randomly assigned to five pairs of raters. Raters assessed infants' GMs using preterm videos. Outcome variables were (a) the GMs classification (normal versus abnormal; normal versus abnormal subcategories) and (b) the general movements optimality score (GMOS), obtained through the global and detailed assessments. The Gwet's AC1 and the intraclass correlation coefficient (ICC) were calculated for the GMs classification and the GMOS, respectively.
RESULTS: The global assessment presented an AC1 = 0.84 [95% CI = 0.54,1] for the GMs binary classification and an AC1 = 0.67 [95% CI = 0.38,0.89] for the GMs classification with abnormal subcategories. The detailed assessment presented an ICC = 0.72 [95% CI = 0.39,0.90] for the GMOS.
CONCLUSIONS: Inter-rater reliability was high and substantial for the global assessment and good for the detailed assessment. However, the small sample size limited the precision of these estimates. Future research should involve larger samples of preterm infants to improve estimate precision. Challenging items such as assessing the neck and trunk, poor repertoire GMs, and tremulous movements may impact the preterm writhing GMA's inter-rater reliability. Therefore, ongoing training and calibration among raters is necessary. Further investigation in clinical settings can enhance our understanding of the preterm writhing GMA's reliability.
Calcineurin inhibitors (CNIs) constitute the backbone of modern acute graft-versus-host disease (aGVHD) prophylaxis regimens but have limited efficacy in the prevention and treatment of chronic GVHD (cGVHD). We investigated the effect of CNIs on immune tolerance after stem cell transplantation with discovery-based single-cell gene expression and T cell receptor (TCR) assays of clonal immunity in tandem with traditional protein-based approaches and preclinical modeling. While cyclosporin and tacrolimus suppressed the clonal expansion of CD8+ T cells during GVHD, alloreactive CD4+ T cell clusters were preferentially expanded. Moreover, CNIs mediated reversible dose-dependent suppression of T cell activation and all stages of donor T cell exhaustion. Critically, CNIs promoted the expansion of both polyclonal and TCR-specific alloreactive central memory CD4+ T cells (TCM) with high self-renewal capacity that mediated cGVHD following drug withdrawal. In contrast to posttransplant cyclophosphamide (PT-Cy), CSA was ineffective in eliminating IL-17A-secreting alloreactive T cell clones that play an important role in the pathogenesis of cGVHD. Collectively, we have shown that, although CNIs attenuate aGVHD, they paradoxically rescue alloantigen-specific TCM, especially within the CD4+ compartment in lymphoid and GVHD target tissues, thus predisposing patients to cGVHD. These data provide further evidence to caution against CNI-based immune suppression without concurrent approaches that eliminate alloreactive T cell clones.
During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 patch for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
FIELD: medicine. SUBSTANCE: B-thymnodonic acid is incubated with preparation of prostaglandin H synthetase at the ratio 0.3-3.3 mcmole [H]-thymnodonic acid per 1 mg prostaglandin H synthetase for 4 min (not more). Then preparation of partially purified thromboxan synthetase is added and incubated at 25 C for 25-40 min. Method can be used for preparing of thromboxane [H]. EFFECT: improved method of product preparing. 1 dwg
Uropathogenic Escherichia coli (UPEC) is a typical cystitis-causing organism that can migrate from the vagina to the bladder and cause recurrent cystitis (RC). Few reports have compared the characteristics of urinary and vaginal UPEC in patients with RC. We carried out molecular biological analyses of Escherichia coli (E. coli) strains and their antimicrobial susceptibility to assess the association between urinary and vaginally UPEC. We included E. coli isolated from urinary and vaginal samples at the onset of cystitis in postmenopausal women with RC between 2014 and 2019 in our hospital. Pulsed-field gel electrophoresis (PFGE) was performed using a restriction enzyme (Xba I). These sequences were compared with 17 antimicrobial susceptibilities determined by a micro-liquid dilution method. Multilocus sequence typing (MLST) and classification of extended-spectrum β-lactamase (ESBL) genotypes by multiplex polymerase chain reaction (PCR) were performed on ESBL-producing E. coli. We analyzed 14 specimens (each seven urine and vaginal) from seven patients in total. On PFGE, the similarity of urinary and vaginal E. coli per patient ranged from 89.5 to 100 %, including four patients with 100 % matches. MLST demonstrated that 29 % (4/14 specimens) were strain sequence type 131. Two specimens contained ESBL-producing strains and identified the CTX-M-27 genotype for each specimen. For each patient, antimicrobial susceptibilities between urinary and vaginal E. coli were mostly identical. Thus, urinary- and vaginally-derived E. coli were identical in postmenopausal women with RC. Management targeting both urinary and vaginal UPEC is essential for RC, indicating the importance of a vagina-targeted approach.
The invention discloses a traditional Chinese medicine compound preparation used for treating nephrotic syndrome hypoproteinemia. Nephritic syndrome hypoproteinemia has clinical indications of plasma-albumin lower than 30g/L, lower extremities edema and hydrothorax and ascites with different degrees, poor appetite, hypodynamia, abdominal distention; or companied skin eczema, and bitter taste and dryness of mouths; or companied purplish mouth, lips or tongues, and purplish and expended sublingual venae. The compound preparation provides functions of spleen strengthening, kidney benefiting, blood circulation promoting, meridian obstruction removing, heat clearing, and dampness eliminating. The compound preparation is an oral preparation composed of an active component extract and medicinal auxiliary materials. The active component extract is at least extracted from black soybean, Mongolian milkvetch root, common yam rhizome, swordlike atractylodes rhizome, ligusticum, and leeches. The invention also discloses an extraction method of the active components and an application thereof in preparing medicines used for preventing and treating nephrotic syndrome hypoproteinemia.